EA200001041A1 - Антитела к cd23, их производные и их терапевтическое применение - Google Patents

Антитела к cd23, их производные и их терапевтическое применение

Info

Publication number
EA200001041A1
EA200001041A1 EA200001041A EA200001041A EA200001041A1 EA 200001041 A1 EA200001041 A1 EA 200001041A1 EA 200001041 A EA200001041 A EA 200001041A EA 200001041 A EA200001041 A EA 200001041A EA 200001041 A1 EA200001041 A1 EA 200001041A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
derivatives
therapeutic application
fcεrii
bind
Prior art date
Application number
EA200001041A
Other languages
English (en)
Inventor
Жан-Ив Марсель Поль Боннефуа
Скотт Джеймс Кроу
Джонатан Генри Эллис
Николас Тимоти Рапсон
Джин Ширин
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA200001041A1 publication Critical patent/EA200001041A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к антителам, которые связываются с молекулой CD23 типа II (FCεRII), в частности к измененным антителам, включая антитела, которые связываются с молекулой CD23 типа II (FCεRII), отличающимся константой аффинности, равной или превышающей Ka 1x10моль, получению таких антител, фармацевтическим композициям, которые содержат такие антитела, и их применению в терапии, особенно при лечении аутоиммунных и воспалительных заболеваний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001041A 1998-05-09 1999-05-07 Антитела к cd23, их производные и их терапевтическое применение EA200001041A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
EA200001041A1 true EA200001041A1 (ru) 2001-06-25

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001041A EA200001041A1 (ru) 1998-05-09 1999-05-07 Антитела к cd23, их производные и их терапевтическое применение

Country Status (25)

Country Link
US (1) US7008623B1 (ru)
EP (1) EP1076701A1 (ru)
JP (1) JP2002514421A (ru)
KR (1) KR20010043470A (ru)
CN (1) CN1308676A (ru)
AP (1) AP1547A (ru)
AU (1) AU763491B2 (ru)
BR (1) BR9910327A (ru)
CA (1) CA2328606A1 (ru)
EA (1) EA200001041A1 (ru)
EE (1) EE200000658A (ru)
GB (1) GB9809839D0 (ru)
HR (1) HRP20000762A2 (ru)
HU (1) HUP0102005A3 (ru)
ID (1) ID28088A (ru)
IL (1) IL139384A0 (ru)
IS (1) IS5696A (ru)
NO (1) NO20005632L (ru)
NZ (1) NZ507879A (ru)
PL (1) PL344019A1 (ru)
SK (1) SK16762000A3 (ru)
TR (1) TR200003281T2 (ru)
WO (1) WO1999058679A1 (ru)
YU (1) YU69000A (ru)
ZA (1) ZA200006312B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
JP2004532608A (ja) 2000-10-13 2004-10-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ヒト化抗ＬＴ−β−Ｒ抗体
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
MXPA06000176A (es) * 2003-12-10 2006-06-27 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y sus metodos de uso.
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
AP2008004467A0 (en) * 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
KR101710472B1 (ko) 2007-11-30 2017-02-27 글락소 그룹 리미티드 항원-결합 작제물
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
US20110064821A1 (en) 2008-05-06 2011-03-17 Catchpole Ian Richard Encapsulation of biologically active agents
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
JP2012518400A (ja) 2009-02-24 2012-08-16 グラクソ グループ リミテッド 多価および／または複数特異的ｒａｎｋｌ結合性構築物
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US20120058116A1 (en) 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
MX2012002464A (es) 2009-08-28 2012-03-14 Rinat Neuroscience Corp El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
FR2957598B1 (fr) * 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
JP6351973B2 (ja) 2010-11-23 2018-07-04 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合タンパク質
BR112013013003A2 (pt) 2010-11-24 2016-08-09 Glaxo Group Ltd proteína de ligação de antígeno, e, composição farmacêutica
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
DK3415531T3 (da) 2011-05-27 2023-09-18 Glaxo Group Ltd Bcma (cd269/tnfrsf17)-bindende proteiner
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
JP6224739B2 (ja) 2013-03-15 2017-11-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 抗ｌａｇ−３結合タンパク質
ES2729317T3 (es) * 2013-07-10 2019-10-31 Onconox Aps Anticuerpos a beta2-glicoproteína I y usos terapéuticos de estos
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
PT3344654T (pt) 2015-09-02 2021-01-26 Immutep Sas Anticorpos anti-lag-3
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
US10479827B2 (en) 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
CA3036632A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
DK0788513T3 (da) * 1994-10-25 2001-04-02 Glaxo Group Ltd Anvendelse af bindingsmidler for CD23 i behandlingen af atoimmune sygdomme
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
AU3836799A (en) 1999-11-29
ZA200006312B (en) 2003-02-26
EE200000658A (et) 2002-04-15
HUP0102005A3 (en) 2003-10-28
CN1308676A (zh) 2001-08-15
AU763491B2 (en) 2003-07-24
ID28088A (id) 2001-05-03
SK16762000A3 (sk) 2001-07-10
GB9809839D0 (en) 1998-07-08
IS5696A (is) 2000-10-31
NZ507879A (en) 2004-02-27
TR200003281T2 (tr) 2001-03-21
HUP0102005A2 (hu) 2001-10-28
IL139384A0 (en) 2001-11-25
YU69000A (sh) 2003-08-29
CA2328606A1 (en) 1999-11-18
JP2002514421A (ja) 2002-05-21
US7008623B1 (en) 2006-03-07
HRP20000762A2 (en) 2001-06-30
PL344019A1 (en) 2001-09-24
WO1999058679A1 (en) 1999-11-18
NO20005632L (no) 2001-01-08
BR9910327A (pt) 2001-01-30
AP2000001983A0 (en) 2000-12-31
KR20010043470A (ko) 2001-05-25
AP1547A (en) 2006-01-13
EP1076701A1 (en) 2001-02-21
NO20005632D0 (no) 2000-11-08

Similar Documents

Publication Publication Date Title
EA200001041A1 (ru) Антитела к cd23, их производные и их терапевтическое применение
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
EA199901063A1 (ru) Пиперазиновые производные и их применение в качестве противовоспалительных агентов
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
EA199800119A1 (ru) Ингибиторы адгезии клеток
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
EA199900559A1 (ru) Замещенные, азотсодержащие гетероциклы в качестве ингибиторов протеинкиназы p38
EP1408986A4 (en) PROTEOMIMETIC COMPOUNDS AND CORRESPONDING METHODS
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200400312A1 (ru) АНТАГОНИСТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFSF13b ЧЕЛОВЕКА
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
EA200300508A1 (ru) Противовоспалительные агенты
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
EA199900621A1 (ru) Лечение рассеянного склероза путем приема внутрь или ингаляции сополимера-1
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1